SBFM (Sunshine Biopharma) Forward P/E Multiple
Sunshine Biopharma (SBFM) revenue dynamics are based on a combination of Canadian generic sales and high-risk developments. The company's forward P/E shift visualizes these fluctuations, where 0.00 describes the current status of the metric. Growth is supported by the creation of a system to combat resistant lung and breast cancer, although drug synthesis and testing have been fully outsourced to external contractors.
Summary analytical data breakdowns for Sunshine Biopharma Inc. (SBFM)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Sunshine Biopharma|SBFM - Long-Term Liabilities to Capital|Short-Term Debt to Equity Sunshine Biopharma Inc.|SBFM - Company Total Debt Obligations|Debt to Book Value Sunshine Biopharma|SBFM - Company Long-Term Debts|Company Short-Term Debt Sunshine Biopharma|Quick Liquidity sunshinebiopharma.com
- financial results and valuation multiples details:
SBFM - Net Financial Result|Projected Future Earnings Sunshine Biopharma|SBFM - Company Value to Net Income|Forward P/E Multiple sunshinebiopharma.com|SBFM - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sunshine Biopharma, Inc.|SBFM - Operating profit before amortization|Net earnings per share (EPS TTM) Sunshine Biopharma|SBFM - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months sunshinebiopharma.com|SBFM - Earnings per share increase in current year|Earnings growth forecast for next year Sunshine Biopharma
- sales volume and revenue indicators:
Basic company analysis:sunshinebiopharma.com SBFM
The forward P/E reflects the ratio of the current market value of Sunshine Biopharma (SBFM) to projected net income, allowing investors to assess the extent of the premium paid for future earnings. By analyzing the forward P/E multiple of Sunshine Biopharma (SBFM), one can correlate it with the stability of oncology drug supplies and logistics diversification, which confirms the fundamental reliability of the business and minimizes the risk of capital stagnation.
Analysis of competing companies
Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TuHURA (HURA) - Forward P/E Multiple|TARA (Protara Therapeutics Inc) - Forward P/E Multiple|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|TCRX (TScan) - Future Price to Earnings Multiple|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT - Projected Price to Earnings|CEL-SCI - Forward P/E Multiple|OSTX - Forward P/E Multiple|Radiopharm Theranostics Limited (RADX) - Future Price to Earnings|ARTV - Market Cap to Projected Earnings|Projected Price to Earnings ANL|Future Price to Earnings VERU|Forward P/E Multiple TPST|XLO: Price to Expected Earnings Ratio|Forward P/E Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Projected Price to Earnings Ratio|Kairos Pharma Ltd - Forward P/E Multiple|Price to Expected Earnings Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Future Price to Earnings|CRIS - Market Cap to Projected Earnings|Projected Price to Earnings APLM|Tharimmune (THAR) - Market Cap to Projected Earnings|Projected Price to Earnings ADVB (Advanced Biomed Inc.)|Genprex - Price to Future Earnings Ratio|Forward P/E Multiple CLDI (Calidi Biotherapeutics, Inc.)|XBIO - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple
